CXCR3 ligands: Redundant, collaborative and antagonistic functions

Immunology and Cell Biology

Volumn 89, Issue 2, 2011, Pages 207-215

  Groom, Joanna R ^a   Luster, Andrew D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

chemokines; CXCL10; CXCL9; CXCR3; T cell trafficking

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10;

BRAIN MALARIA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INTERACTION; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; EFFECTOR CELL; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; LIGAND BINDING; LYMPHOCYTE MIGRATION; LYMPHOCYTIC INFILTRATION; LYMPHOID ORGAN; MOLECULAR INTERACTION; NATURAL KILLER T CELL; NEUROPATHOLOGY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; RECEPTOR BINDING; REVIEW; T LYMPHOCYTE ACTIVATION; TH1 CELL;

ANIMALS; HUMANS; LIGANDS; MODELS, IMMUNOLOGICAL; RECEPTORS, CXCR3;

EID: 79951944636     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2010.158     Document Type: Review

References (176)

1. Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I et al. Chemokine receptor specific for IP10 and Mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 1996; 184: 963-969.
2. Loetscher M, Loetscher P, Brass N, Meese E, Moser B. Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur J Immunol 1998; 28: 3696-3705. (Pubitemid 28510780)
3. Kim CH, Rott L, Kunkel EJ, Genovese MC, Andrew DP, Wu L et al. Rules of chemokine receptor association with T cell polarization in vivo. J Clin Invest 2001; 108: 1331-1339. (Pubitemid 33107761)
4. Yamamoto J, Adachi Y, Onoue Y, Adachi YS, Okabe Y, Itazawa T et al. Differential expression of the chemokine receptors by the Th1- and Th2-type effector populations within circulating CD4+ T cells. J Leukoc Biol 2000; 68: 568-574.
5. Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, Loetscher M et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998; 101: 746-754. (Pubitemid 28096070)
6. Shields PL, Morland CM, Salmon M, Qin S, Hubscher SG, Adams DH. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J Immunol 1999; 163: 6236-6243.
7. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 1998; 187: 875-883. (Pubitemid 28141661)
8. Xie JH, Nomura N, Lu M, Chen SL, Koch GE, Weng Y et al. Antibody-mediated blockade of the CXCR3 chemokine receptor results in diminished recruitment of T helper 1 cells into sites of inflammation. J Leukoc Biol 2003; 73: 771-780. (Pubitemid 38040456)
9. Guarda G, Hons M, Soriano SF, Huang AY, Polley R, Martin-Fontecha A et al. L-selectin-negative CCR7- effector and memory CD8+ T cells enter reactive lymph nodes and kill dendritic cells. Nat Immunol 2007; 8: 743-752. (Pubitemid 46965350)
10. Hikono H, Kohlmeier JE, Takamura S, Wittmer ST, Roberts AD, Woodland DL. Activation phenotype, rather than central- or effector-memory phenotype, predicts the recall efficacy of memory CD8+ T cells. J Exp Med 2007; 204: 1625-1636. (Pubitemid 47048029)
11. Kim CH, Nagata K, Butcher EC. Dendritic cells support sequential reprogramming of chemoattractant receptor profiles during naive to effector T cell differentiation. J Immunol 2003; 171: 152-158. (Pubitemid 36745283)
12. Rivino L, Messi M, Jarrossay D, Lanzavecchia A, Sallusto F, Geginat J. Chemokine receptor expression identifies Pre-T helper (Th)1, Pre-Th2, and nonpolarized cells among human CD4+ central memory T cells. J Exp Med 2004; 200: 725-735.
13. Beima KM, Miazgowicz MM, Lewis MD, Yan PS, Huang TH, Weinmann AS. T-bet binding to newly identified target gene promoters is cell type-independent but results in variable context-dependent functional effects. J Biol Chem 2006; 281: 11992-12000. (Pubitemid 43855463)
14. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000; 100: 655-669.
15. Szabo SJ, Sullivan BM, Stemmann C, Satoskar AR, Sleckman BP, Glimcher LH. Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells. Science 2002; 295: 338-342. (Pubitemid 34074366)
16. Lord GM, Rao RM, Choe H, Sullivan BM, Lichtman AH, Luscinskas FW et al. T-bet is required for optimal proinflammatory CD4+ T-cell trafficking. Blood 2005; 106: 3432-3439. (Pubitemid 41609178)
17. Khan IA, MacLean JA, Lee FS, Casciotti L, DeHaan E, Schwartzman JD et al. IP-10 is critical for effector T cell trafficking and host survival in Toxoplasma gondii infection. Immunity 2000; 12: 483-494.
18. Campanella GS, Medoff BD, Manice LA, Colvin RA, Luster AD. Development of a novel chemokine-mediated in vivo T cell recruitment assay. J Immunol Methods 2008; 331: 127-139.
19. Thomas SY, Hou R, Boyson JE, Means TK, Hess C, Olson DP et al. CD1d-restricted NKT cells express a chemokine receptor profile indicative of Th1-type inflammatory homing cells. J Immunol 2003; 171: 2571-2580. (Pubitemid 37025568)
20. Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanzavecchia A et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 1999; 5: 919-923. (Pubitemid 29372419)
21. Nanki T, Takada K, Komano Y, Morio T, Kanegane H, Nakajima A et al. Chemokine receptor expression and functional effects of chemokines on B cells: implication in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther 2009; 11: R149.
22. Nakanishi Y, Lu B, Gerard C, Iwasaki A. CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature 2009; 462: 510-513.
23. Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998; 187: 2009-2021. (Pubitemid 28285570)
24. Lu B, Humbles A, Bota D, Gerard C, Moser B, Soler D et al. Structure and function of the murine chemokine receptor CXCR3. Eur J Immunol 1999; 29: 3804-3812. (Pubitemid 29527830)
25. Luster AD, Unkeless JC, Ravetch JV. Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 1985; 315: 672-676. (Pubitemid 15232881)
26. Farber JM. A macrophage mRNA selectively induced by gamma-interferon encodes a member of the platelet factor 4 family of cytokines. Proc Natl Acad Sci USA 1990; 87: 5238-5242.
27. Majumder S, Zhou LZ, Chaturvedi P, Babcock G, Aras S, Ransohoff RM. p48/STAT-1alpha-containing complexes play a predominant role in induction of IFN-gamma-inducible protein, 10 kDa (IP-10) by IFN-gamma alone or in synergy with TNF-alpha. J Immunol 1998; 161: 4736-4744. (Pubitemid 28492049)
28. Ohmori Y, Hamilton TA. Cooperative interaction between interferon (IFN) stimulus response element and kappa B sequence motifs controls IFN gamma- and lipopolysaccharide-stimulated transcription from the murine IP-10 promoter. J Biol Chem 1993; 268: 6677-6688. (Pubitemid 23099373)
29. Ohmori Y, Hamilton TA. IL-4-induced STAT6 suppresses IFN-gamma-stimulated STAT1-dependent transcription in mouse macrophages. J Immunol 1997; 159: 5474-5482. (Pubitemid 127470075)
30. Wong P, Severns CW, Guyer NB, Wright TM. A unique palindromic element mediates gamma interferon induction of mig gene expression. Mol Cell Biol 1994; 14: 914-922. (Pubitemid 24036541)
31. Wright TM, Farber JM. 5′ regulatory region of a novel cytokine gene mediates selective activation by interferon gamma. J Exp Med 1991; 173: 417-422.
32. Tensen CP, Flier J, Rampersad SS, Sampat-Sardjoepersad S, Scheper RJ, Boorsma DM et al. Genomic organization, sequence and transcriptional regulation of the human CXCL 11(1) gene. Biochim Biophys Acta 1999; 1446: 167-172.
33. Yang CH, Wei L, Pfeffer SR, Du Z, Murti A, Valentine WJ et al. Identification of CXCL11 as a STAT3-dependent gene induced by IFN. J Immunol 2007; 178: 986-992. (Pubitemid 46095172)
34. Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 1997; 61: 246-257. (Pubitemid 27149903)
35. Ohmori Y, Wyner L, Narumi S, Armstrong D, Stoler M, Hamilton TA. Tumor necrosis factor-alpha induces cell type and tissue-specific expression of chemoattractant cytokines in vivo. Am J Pathol 1993; 142: 861-870. (Pubitemid 24064004)
36. Ohmori Y, Schreiber RD, Hamilton TA. Synergy between interferon-gamma and tumor necrosis factor-alpha in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor kappaB. J Biol Chem 1997; 272: 14899-14907. (Pubitemid 27251761)
37. Rani MR, Foster GR, Leung S, Leaman D, Stark GR, Ransohoff RM. Characterization of beta-R1, a gene that is selectively induced by interferon beta (IFN-beta) compared with IFN-alpha. J Biol Chem 1996; 271: 22878-22884. (Pubitemid 26304738)
38. Medoff BD, Wain JC, Seung E, Jackobek R, Means TK, Ginns LC et al. CXCR3 and its ligands in a murine model of obliterative bronchiolitis: regulation and function. J Immunol 2006; 176: 7087-7095. (Pubitemid 43787890)
39. Wang Q, Nagarkar DR, Bowman ER, Schneider D, Gosangi B, Lei J et al. Role of double-stranded RNA pattern recognition receptors in rhinovirus-induced airway epithelial cell responses. J Immunol 2009; 183: 6989-6997.
40. Qian C, An H, Yu Y, Liu S, Cao X. TLR agonists induce regulatory dendritic cells to recruit Th1 cells via preferential IP-10 secretion and inhibit Th1 proliferation. Blood 2007; 109: 3308-3315.
41. Hancock WW, Gao W, Csizmadia V, Faia KL, Shemmeri N, Luster AD. Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med 2001; 193: 975-980. (Pubitemid 32525870)
42. Campanella GS, Tager AM, El Khoury JK, Thomas SY, Abrazinski TA, Manice LA et al. Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the development of murine cerebral malaria. Proc Natl Acad Sci USA 2008; 105: 4814-4819. (Pubitemid 351753829)
43. Weng Y, Siciliano SJ, Waldburger KE, Sirotina-Meisher A, Staruch MJ, Daugherty BL et al. Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors. J Biol Chem 1998; 273: 18288-18291. (Pubitemid 28334752)
44. Cox MA, Jenh CH, Gonsiorek W, Fine J, Narula SK, Zavodny PJ et al. Human interferon-inducible 10-kDa protein and human interferon-inducible T cell alpha chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states. Mol Pharmacol 2001; 59: 707-715. (Pubitemid 32273999)
45. Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998; 187: 2009-2021. (Pubitemid 28285570)
46. Meyer M, Hensbergen PJ, van der Raaij-Helmer EM, Brandacher G, Margreiter R, Heufler C et al. Cross reactivity of three T cell attracting murine chemokines stimulating the CXC chemokine receptor CXCR3 and their induction in cultured cells and during allograft rejection. Eur J Immunol 2001; 31: 2521-2527. (Pubitemid 32791305)
47. Colvin RA, Campanella GS, Manice LA, Luster AD. CXCR3 requires tyrosine sulfation for ligand binding and a second extracellular loop arginine residue for ligand-induced chemotaxis. Mol Cell Biol 2006; 26: 5838-5849. (Pubitemid 44134338)
48. Colvin RA, Campanella GS, Sun J, Luster AD. Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. J Biol Chem 2004; 279: 30219-30227. (Pubitemid 38937947)
49. Clark-Lewis I, Mattioli I, Gong JH, Loetscher P. Structure-function relationship between the human chemokine receptor CXCR3 and its ligands. J Biol Chem 2003; 278: 289-295. (Pubitemid 36043575)
50. Campanella GS, Lee EM, Sun J, Luster AD. CXCR3 and heparin binding sites of the chemokine IP-10 (CXCL10). J Biol Chem 2003; 278: 17066-17074. (Pubitemid 36799583)
51. Severin IC, Gaudry JP, Johnson Z, Kungl A, Jansma A, Gesslbauer B et al. Characterization of the chemokine CXCL11-heparin interaction suggests two different affinities for glycosaminoglycans. J Biol Chem 2010; 285: 17713-17724.
52. Wang P, Yang X, Xu W, Li K, Chu Y, Xiong S. Integrating individual functional moieties of CXCL10 and CXCL11 into a novel chimeric chemokine leads to synergistic antitumor effects: a strategy for chemokine-based multi-target-directed cancer therapy. Cancer Immunol Immunother 2010; 59: 1715-1726.
53. Loetscher P, Pellegrino A, Gong JH, Mattioli I, Loetscher M, Bardi G et al. The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J Biol Chem 2001; 276: 2986-2991.
54. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006; 203: 2201-2213. (Pubitemid 44352240)
55. Naumann U, Cameroni E, Pruenster M, Mahabaleshwar H, Raz E, Zerwes HG et al. CXCR7 functions as a scavenger for CXCL12 and CXCL11. PLoS One 2010; 5: e9175.
56. Luster AD, Greenberg S, Leder P. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med 1995; 182: 219-231.
57. Campanella GS, Grimm J, Manice LA, Colvin RA, Medoff BD, Wojtkiewicz GR et al. Oligomerization of CXCL10 is necessary for endothelial cell presentation and in vivo activity. J Immunol 2006; 177: 6991-6998. (Pubitemid 44715065)
58. Campanella GS, Colvin RA, Luster AD. CXCL10 can inhibit endothelial cell proliferation independently of CXCR3. PLoS One 2010; 5: e12700.
59. Jiang D, Liang J, Campanella GS, Guo R, Yu S, Xie T et al. Inhibition of pulmonary fibrosis in mice by CXCL10 requires glycosaminoglycan binding and syndecan-4. J Clin Invest 2010; 120: 2049-2057.
60. Tager AM, Kradin RL, LaCamera P, Bercury SD, Campanella GS, Leary CP et al. Inhibition of pulmonary fibrosis by the chemokine IP-10/CXCL10. Am J Respir Cell Mol Biol 2004; 31: 395-404. (Pubitemid 39330949)
61. Luster AD, Cardiff RD, MacLean JA, Granstein RD. Delayed wound healing and disorganized neovascularization in transgenic mice expressing the IP-10 chemokine. Proc Assoc Amer Phys 1998; 110: 183-196. (Pubitemid 28235170)
62. Proost P, Schutyser E, Menten P, Struyf S, Wuyts A, Opdenakker G et al. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 2001; 98: 3554-3561.
63. Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J ExpMed 1995; 182: 155-162.
64. Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 2002; 168: 3195-3204. (Pubitemid 34256349)
65. Park MK, Amichay D, Love P, Wick E, Liao F, Grinberg A et al. The CXC chemokine murine monokine induced by IFN-gamma (CXC chemokine ligand 9) is made by APCs, targets lymphocytes including activated B cells, and supports antibody responses to a bacterial pathogen in vivo. J Immunol 2002; 169: 1433-1443. (Pubitemid 34811943)
66. Hsieh MF, Lai SL, Chen JP, Sung JM, Lin YL, Wu-Hsieh BA et al. Both CXCR3 and CXCL10/IFN-inducible protein 10 are required for resistance to primary infection by dengue virus. J Immunol 2006; 177: 1855-1863. (Pubitemid 44092524)
67. Klein RS, Lin E, Zhang B, Luster AD, Tollett J, Samuel MA et al. Neuronal CXCL10 directs CD8+ T-cell recruitment and control of West Nile virus encephalitis. J Virol 2005; 79: 11457-11466. (Pubitemid 41170686)
68. Christensen JE, de Lemos C, Moos T, Christensen JP, Thomsen AR. CXCL10 is the key ligand for CXCR3 on CD8+ effector T cells involved in immune surveillance of the lymphocytic choriomeningitis virus-infected central nervous system. J Immunol 2006; 176: 4235-4243. (Pubitemid 44264402)
69. Christen U, McGavern DB, Luster AD, von Herrath MG, Oldstone MB. Among CXCR3 chemokines, IFN-gamma-inducible protein of 10 kDa (CXC chemokine ligand (CXCL) 10) but not monokine induced by IFN-gamma (CXCL9) imprints a pattern for the subsequent development of autoimmune disease. J Immunol 2003; 171: 6838-6845.
70. Frigerio S, Junt T, Lu B, Gerard C, Zumsteg U, Hollander GA et al. Beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis. Nat Med 2002; 8: 1414-1420. (Pubitemid 36024137)
71. Zhang Z, Kaptanoglu L, Haddad W, Ivancic D, Alnadjim Z, Hurst S et al. Donor T cell activation initiates small bowel allograft rejection through an IFN-gamma-inducible protein-10-dependent mechanism. J Immunol 2002; 168: 3205-3212. (Pubitemid 34250379)
72. Zhang Z, Kaptanoglu L, Tang Y, Ivancic D, Rao SM, Luster A et al. IP-10-induced recruitment of CXCR3 host T cells is required for small bowel allograft rejection. Gastroenterology 2004; 126: 809-818. (Pubitemid 38298329)
73. Hyun JG, Lee G, Brown JB, Grimm GR, Tang Y, Mittal N et al. Anti-interferon-inducible chemokine CXCL10, reduces colitis by impairing T helper-1 induction and recruitment in mice. Inflamm Bowel Dis 2005; 11: 799-805. (Pubitemid 41368267)
74. Singh UP, Singh S, Singh R, Cong Y, Taub DD, Lillard Jr JW. CXCL10-producing mucosal CD4+ T cells, NK cells, and NKT cells are associated with chronic colitis in IL-10(-/-) mice, which can be abrogated by anti-CXCL10 antibody inhibition. J Interferon Cytokine Res 2008; 28: 31-43. (Pubitemid 351171383)
75. Menke J, Zeller GC, Kikawada E, Means TK, Huang XR, Lan HY et al. CXCL9, but not CXCL10, promotes CXCR3-dependent immune-mediated kidney disease. J Am Soc Nephrol 2008; 19: 1177-1189.
76. Steinmetz OM, Turner JE, Paust HJ, Lindner M, Peters A, Heiss K et al. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis. J Immunol 2009; 183: 4693-4704.
77. Li B, Xu W, Xu L, Jiang Z, Wen Z, Li K et al. I-TAC is a dominant chemokine in controlling skin intragraft inflammation via recruiting CXCR3+ cells into the graft. Cell Immunol 2010; 260: 83-91.
78. Miu J, Mitchell AJ, Muller M, Carter SL, Manders PM, McQuillan JA et al. Chemokine gene expression during fatal murine cerebral malaria and protection due to CXCR3 deficiency. J Immunol 2008; 180: 1217-1230.
79. Nie CQ, Bernard NJ, Norman MU, Amante FH, Lundie RJ, Crabb BS et al. IP-10-mediated T cell homing promotes cerebral inflammation over splenic immunity to malaria infection. PLoS Pathog 2009; 5: e1000369.
80. Thapa M, Welner RS, Pelayo R, Carr DJ. CXCL9 and CXCL10 expression are critical for control of genital herpes simplex virus type 2 infection through mobilization of HSV-specific CTL and NK cells to the nervous system. J Immunol 2008; 180: 1098-1106.
81. Yoneyama H, Narumi S, Zhang Y, Murai M, Baggiolini M, Lanzavecchia A et al. Pivotal role of dendritic cell-derived CXCL10 in the retention of T helper cell 1 lymphocytes in secondary lymph nodes. J Exp Med 2002; 195: 1257-1266. (Pubitemid 34564328)
82. Yoon SH, Yun SO, Park JY, Won HY, Kim EK, Sohn HJ et al. Selective addition of CXCR3(+) CCR4(-) CD4(+) Th1 cells enhances generation of cytotoxic T cells by dendritic cells in vitro. Exp Mol Med 2009; 41: 161-170.
83. Kohlmeier JE, Cookenham T, Miller SC, Roberts AD, Christensen JP, Thomsen AR et al. CXCR3 directs antigen-specific effector CD4+ T cell migration to the lung during parainfluenza virus infection. J Immunol 2009; 183: 4378-4384.
84. Rosenblum JM, Shimoda N, Schenk AD, Zhang H, Kish DD, Keslar K et al. CXC chemokine ligand (CXCL) 9 and CXCL10 are antagonistic costimulation molecules during the priming of alloreactive T cell effectors. J Immunol 2010; 184: 3450-3460.
85. Wuest T, Farber J, Luster A, Carr DJ. CD4+ T cell migration into the cornea is reduced in CXCL9 deficient but not CXCL10 deficient mice following herpes simplex virus type 1 infection. Cell Immunol 2006; 243: 83-89. (Pubitemid 46428226)
86. Rosenblum JM, Zhang QW, Siu G, Collins TL, Sullivan T, Dairaghi DJ et al. CXCR3 antagonism impairs the development of donor-reactive, IFN-gamma-producing effectors and prolongs allograft survival. Transplantation 2009; 87: 360-369.
87. Koch MA, Tucker-Heard G, Perdue NR, Killebrew JR, Urdahl KB, Campbell DJ. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol 2009; 10: 595-602.
88. Miura M, Morita K, Kobayashi H, Hamilton TA, Burdick MD, Strieter RM et al. Monokine induced by IFN-gamma is a dominant factor directing T cells into murine cardiac allografts during acute rejection. J Immunol 2001; 167: 3494-3504. (Pubitemid 32852596)
89. Belperio JA, Keane MP, Burdick MD, Lynch III JP, Xue YY, Li K et al. Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome. J Immunol 2002; 169: 1037-1049. (Pubitemid 34753464)
90. Kobayashi H, Novick AC, Toma H, Fairchild RL. Chronic antagonism of Mig inhibits cellular infiltration and promotes survival of class II MHC disparate skin allografts. Transplantation 2002; 74: 387-395.
91. Flier J, Boorsma DM, van Beek PJ, Nieboer C, Stoof TJ, Willemze R et al. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol 2001; 194: 398-405. (Pubitemid 32782663)
92. Goebeler M, Toksoy A, Spandau U, Engelhardt E, Brocker EB, Gillitzer R. The C-X-C chemokine Mig is highly expressed in the papillae of psoriatic lesions. J Pathol 1998; 184: 89-95. (Pubitemid 28086159)
93. Gottlieb AB, Luster AD, Posnett DN, Carter DM. Detection of a gamma interferon-induced protein IP-10 in psoriatic plaques. J Exp Med 1988; 168: 941-948.
94. Agostini C, Cassatella M, Sancetta R, Zambello R, Trentin L, Gasperini S et al. Involvement of the IP-10 chemokine in sarcoid granulomatous reactions. J Immunol 1998; 161: 6413-6420. (Pubitemid 28536019)
95. Busuttil A, Weigt SS, Keane MP, Xue YY, Palchevskiy V, Burdick MD et al. CXCR3 ligands are augmented during the pathogenesis of pulmonary sarcoidosis. Eur Respir J 2009; 34: 676-686.
96. Nishioka Y, Manabe K, Kishi J, Wang W, Inayama M, Azuma M et al. CXCL9 and 11 in patients with pulmonary sarcoidosis: a role of alveolar macrophages. Clin Exp Immunol 2007; 149: 317-326. (Pubitemid 47063058)
97. Qin S, Rottman JB, Myrers P, Kassam N, Weinblatt M, Loetscher M et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998; 101: 746-754. (Pubitemid 28096070)
98. Tsubaki T, Takegawa S, Hanamoto H, Arita N, Kamogawa J, Yamamoto H et al. Accumulation of plasma cells expressing CXCR3 in the synovial sublining regions of early rheumatoid arthritis in association with production of Mig/CXCL9 by synovial fibroblasts. Clin Exp Immunol 2005; 141: 363-371. (Pubitemid 41003361)
99. Martini G, Zulian F, Calabrese F, Bortoli M, Facco M, Cabrelle A et al. CXCR3/CXCL10 expression in the synovium of children with juvenile idiopathic arthritis. Arthritis Res Ther 2005; 7: R241-R249.
100. Mohan K, Issekutz TB. Blockade of chemokine receptor CXCR3 inhibits T cell recruitment to inflamed joints and decreases the severity of adjuvant arthritis. J Immunol 2007; 179: 8463-8469.
101. Salomon I, Netzer N, Wildbaum G, Schif-Zuck S, Maor G, Karin N. Targeting the function of IFN-gamma-inducible protein 10 suppresses ongoing adjuvant arthritis. J Immunol 2002; 169: 2685-2693. (Pubitemid 34921017)
102. Thomas SY, Banerji A, Medoff BD, Lilly CM, Luster AD. Multiple chemokine receptors, including CCR6 and CXCR3, regulate antigen-induced T cell homing to the human asthmatic airway. J Immunol 2007; 179: 1901-1912.
103. Campbell JJ, Brightling CE, Symon FA, Qin S, Murphy KE, Hodge M et al. Expression of chemokine receptors by lung T cells from normal and asthmatic subjects. J Immunol 2001; 166: 2842-2848. (Pubitemid 32173526)
104. Medoff BD, Sauty A, Tager AM, Maclean JA, Smith RN, Mathew A et al. IFN-gamma-inducible protein 10 (CXCL10) contributes to airway hyperreactivity and airway inflammation in a mouse model of asthma. J Immunol 2002; 168: 5278-5286. (Pubitemid 34495996)
105. Suzaki Y, Hamada K, Nomi T, Ito T, Sho M, Kai Y et al. A small-molecule compound targeting CCR5 and CXCR3 prevents airway hyperresponsiveness and inflammation. Eur Respir J 2008; 31: 783-789.
106. Bochner BS, Hudson SA, Xiao HQ, Liu MC. Release of both CCR4-active and CXCR3-active chemokines during human allergic pulmonary late-phase reactions. J Allergy Clin Immunol 2003; 112: 930-934. (Pubitemid 37412061)
107. Mach F, Sauty A, Iarossi AS, Sukhova GK, Neote K, Libby P et al. The interferon-gamma inducible CXC chemokines IP-10, Mig, and I-TAC are differentially expressed by human atheroma-associated cells: implications for lymphocyte recruitment in atherogenesis. J Clin Invest 1999; 104: 1041-1050.
108. Veillard NR, Steffens S, Pelli G, Lu B, Kwak BR, Gerard C et al. Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo. Circulation 2005; 112: 870-878. (Pubitemid 41170074)
109. Heller EA, Liu E, Tager AM, Yuan Q, Lin AY, Ahluwalia N et al. Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation 2006; 113: 2301-2312. (Pubitemid 43947976)
110. Sorensen TL, Trebst C, Kivisakk P, Klaege KL, Majmudar A, Ravid R et al. Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system. J Neuroimmunol 2002; 127: 59-68. (Pubitemid 34603575)
111. Sorensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999; 103: 807-815. (Pubitemid 29152626)
112. Balashov K, Rottman J, Weiner H, Hancock W. CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1 and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci USA 1999; 96: 6873-6878. (Pubitemid 29274977)
113. Sporici R, Issekutz TB. CXCR3 blockade inhibits T-cell migration into the CNS during EAE and prevents development of adoptively transferred, but not actively induced, disease. Eur J Immunol 2010; 40: 2751-2761.
114. Kohler RE, Comerford I, Townley S, Haylock-Jacobs S, Clark-Lewis I, McColl SR. Antagonism of the chemokine receptors CXCR3 and CXCR4 reduces the pathology of experimental autoimmune encephalomyelitis. Brain Pathol 2008; 18: 504-516.
115. Muller M, Carter SL, Hofer MJ, Manders P, Getts DR, Getts MT et al. CXCR3 signaling reduces the severity of experimental autoimmune encephalomyelitis by controlling the parenchymal distribution of effector and regulatory T cells in the central nervous system. J Immunol 2007; 179: 2774-2786.
116. Liu L, Huang D, Matsui M, He TT, Hu T, Demartino J et al. Severe disease, unaltered leukocyte migration, and reduced IFN-gamma production in CXCR3-/- mice with experimental autoimmune encephalomyelitis. J Immunol 2006; 176: 4399-4409. (Pubitemid 44264420)
117. Wildbaum G, Netzer N, Karin N. Plasmid DNA encoding IFN-gamma-inducible protein 10 redirects antigen-specific T cell polarization and suppresses experimental autoimmune encephalomyelitis. J Immunol 2002; 168: 5885-5892. (Pubitemid 34556177)
118. Klein RS, Izikson L, Means T, Gibson HD, Lin E, Sobel RA et al. IFN-inducible protein 10/CXC chemokine ligand 10-independent induction of experimental autoimmune encephalomyelitis. J Immunol 2004; 172: 550-559. (Pubitemid 38020512)
119. Schroepf S, Kappler R, Brand S, Prell C, Lohse P, Glas J et al. Strong overexpression of CXCR3 axis components in childhood inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 1882-1890.
120. Pignatti P, Brunetti G, Moretto D, Yacoub MR, Fiori M, Balbi B et al. Role of the chemokine receptors CXCR3 and CCR4 in human pulmonary fibrosis. Am J Respir Crit Care Med 2006; 173: 310-317. (Pubitemid 43209086)
121. Jiang D, Liang J, Hodge J, Lu B, Zhu Z, Yu S et al. Regulation of pulmonary fibrosis by chemokine receptor CXCR3. J Clin Invest 2004; 114: 291-299. (Pubitemid 39071634)
122. Burdick MD, Murray LA, Keane MP, Xue YY, Zisman DA, Belperio JA et al. CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. Am J Respir Crit Care Med 2005; 171: 261-268.
123. Uno S, Imagawa A, Saisho K, Okita K, Iwahashi H, Hanafusa T et al. Expression of chemokines CXC chemokine ligand 10 (CXCL10) and CXCR3 in the inflamed islets of patients with recent-onset autoimmune type 1 diabetes. Endocr J 2010; 57: 991-996.
124. Roep BO, Kleijwegt FS, van Halteren AG, Bonato V, Boggi U, Vendrame F et al. Islet inflammation and CXCL10 in recent-onset type 1 diabetes. Clin Exp Immunol 2010; 159: 338-343.
125. Enghard P, Humrich JY, Rudolph B, Rosenberger S, Biesen R, Kuhn A et al. CXCR3+CD4+ T cells are enriched in inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in systemic lupus erythematosus patients. Arthritis Rheum 2009; 60: 199-206.
126. Kong KO, Tan AW, Thong BY, Lian TY, Cheng YK, Teh CL et al. Enhanced expression of interferon-inducible protein-10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus. Clin Exp Immunol 2009; 156: 134-140.
127. Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 2009; 60: 3098-3107.
128. Saetta M, Mariani M, Panina-Bordignon P, Turato G, Buonsanti C, Baraldo S et al. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 165: 1404-1409. (Pubitemid 34522945)
129. Nie L, Xiang R, Zhou W, Lu B, Cheng D, Gao J. Attenuation of acute lung inflammation induced by cigarette smoke in CXCR3 knockout mice. Respir Res 2008; 9: 82.
130. Nie L, Xiang RL, Liu Y, Zhou WX, Jiang L, Lu B et al. Acute pulmonary inflammation is inhibited in CXCR3 knockout mice after short-term cigarette smoke exposure. Acta Pharmacol Sin 2008; 29: 1432-1439.
131. Brozyna S, Ahern J, Hodge G, Nairn J, Holmes M, Reynolds PN et al. Chemotactic mediators of Th1 T-cell trafficking in smokers and COPD patients. COPD 2009; 6: 4-16.
132. Taqueti VR, Grabie N, Colvin R, Pang H, Jarolim P, Luster AD et al. T-bet controls pathogenicity of CTLs in the heart by separable effects on migration and effector activity. J Immunol 2006; 177: 5890-5901. (Pubitemid 44628802)
133. Yuan J, Liu Z, Lim T, Zhang H, He J, Walker E et al. CXCL10 inhibits viral replication through recruitment of natural killer cells in coxsackievirus B3-induced myocarditis. Circ Res 2009; 104: 628-638.
134. Hancock WW, Lu B, Gao W, Csizmadia V, Faia K, King JA et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000; 192: 1515-1520.
135. Uppaluri R, Sheehan KC, Wang L, Bui JD, Brotman JJ, Lu B et al. Prolongation of cardiac and islet allograft survival by a blocking hamster anti-mouse CXCR3 monoclonal antibody. Transplantation 2008; 86: 137-147.
136. Zerwes HG, Li J, Kovarik J, Streiff M, Hofmann M, Roth L et al. The chemokine receptor Cxcr3 is not essential for acute cardiac allograft rejection in mice and rats. Am J Transplant 2008; 8: 1604-1613.
137. Kwun J, Hazinedaroglu SM, Schadde E, Kayaoglu HA, Fechner J, Hu HZ et al. Unaltered graft survival and intragraft lymphocytes infiltration in the cardiac allograft of Cxcr3-/- mouse recipients. Am J Transplant 2008; 8: 1593-1603.
138. Fahmy NM, Yamani MH, Starling RC, Ratliff NB, Young JB, McCarthy PM et al. Chemokine and chemokine receptor gene expression indicates acute rejection of human cardiac transplants. Transplantation 2003; 75: 72-78. (Pubitemid 36139698)
139. Melter M, Exeni A, Reinders ME, Fang JC, McMahon G, Ganz P et al. Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation 2001; 104: 2558-2564. (Pubitemid 33104793)
140. Agostini C, Calabrese F, Rea F, Facco M, Tosoni A, Loy M et al. CXCR3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. Am J Pathol 2001; 158: 1703-1711. (Pubitemid 32422935)
141. Piper KP, Horlock C, Curnow SJ, Arrazi J, Nicholls S, Mahendra P et al. CXCL10-CXCR3 interactions play an important role in the pathogenesis of acute graft-versushost disease in the skin following allogeneic stem-cell transplantation. Blood 2007; 110: 3827-3832. (Pubitemid 350248437)
142. Mapara MY, Leng C, Kim YM, Bronson R, Lokshin A, Luster A et al. Expression of chemokines in GVHD target organs is influenced by conditioning and genetic factors and amplified by GVHR. Biol Blood Marrow Transplant 2006; 12: 623-634.
143. Kaplan G, Luster AD, Hancock G, Cohn ZA. The expression of a gamma interferon-induced protein (IP-10) in delayed immune responses in human skin. J Exp Med 1987; 166: 1098-1108. (Pubitemid 18024249)
144. Sauty A, Dziejman M, Taha RA, Iarossi AS, Neote K, Garcia-Zepeda EA et al. The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells. J Immunol 1999; 162: 3549-3558. (Pubitemid 29313608)
145. Whittaker E, Gordon A, Kampmann B. Is IP-10 a better biomarker for active and latent tuberculosis in children than IFN gamma? PLoS One 2008; 3: e3901.
146. Fadel SA, Bromley SK, Medoff BD, Luster AD. CXCR3-deficiency protects influenza-infected CCR5-deficient mice from mortality. Eur J Immunol 2008; 38: 3376-3387.
147. Wareing MD, Lyon AB, Lu B, Gerard C, Sarawar SR. Chemokine expression during the development and resolution of a pulmonary leukocyte response to influenza A virus infection in mice. J Leukoc Biol 2004; 76: 886-895. (Pubitemid 39313726)
148. Norose K, Kikumura A, Luster AD, Hunter CA, Harris TH. CXCL10 is required to maintain T cell populations and control parasite replication during chronic ocular toxoplasmosis. Invest Ophthalmol Vis Sci 2010 (e-pub ahead of print).
149. Armah HB, Wilson NO, Sarfo BY, Powell MD, Bond VC, Anderson W et al. Cerebrospinal fluid and serum biomarkers of cerebral malaria mortality in Ghanaian children. Malar J 2007; 6: 147.
150. Becerra A, Warke RV, Martin K, Xhaja K, de Bosch N, Rothman AL et al. Gene expression profiling of dengue infected human primary cells identifies secreted mediators in vivo. J Med Virol 2009; 81: 1403-1411.
151. Zeremski M, Petrovic LM, Chiriboga L, Brown QB, Yee HT, Kinkhabwala M et al. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 2008; 48: 1440-1450.
152. Apolinario A, Majano PL, Alvarez-Perez E, Saez A, Lozano C, Vargas J et al. Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease. Am J Gastroenterol 2002; 97: 2861-2870. (Pubitemid 35265441)
153. Askarieh G, Alsio A, Pugnale P, Negro F, Ferrari C, Neumann AU et al. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology 2010; 51: 1523-1530.
154. Liu MT, Chen BP, Oertel P, Buchmeier MJ, Armstrong D, Hamilton TA et al. The T cell chemoattractant IFN-inducible protein 10 is essential in host defense against viral-induced neurologic disease. J Immunol 2000; 165: 2327-2330. (Pubitemid 30660672)
155. Theil D, Derfuss T, Paripovic I, Herberger S, Meinl E, Schueler O et al. Latent herpesvirus infection in human trigeminal ganglia causes chronic immune response. Am J Pathol 2003; 163: 2179-2184. (Pubitemid 37466462)
156. Carr DJ, Chodosh J, Ash J, Lane TE. Effect of anti-CXCL10 monoclonal antibody on herpes simplex virus type 1 keratitis and retinal infection. J Virol 2003; 77: 10037-10046. (Pubitemid 37122085)
157. Brainard DM, Tager AM, Misdraji J, Frahm N, Lichterfeld M, Draenert R et al. Decreased CXCR3+ CD8 T cells in advanced human immunodeficiency virus infection suggest that a homing defect contributes to cytotoxic T-lymphocyte dysfunction. J Virol 2007; 81: 8439-8450. (Pubitemid 47242817)
158. Foley JF, Yu CR, Solow R, Yacobucci M, Peden KW, Farber JM. Roles for CXC chemokine ligands 10 and 11 in recruiting CD4+ T cells to HIV-1-infected monocyte- derived macrophages, dendritic cells, and lymph nodes. J Immunol 2005; 174: 4892-4900.
159. Kolb SA, Sporer B, Lahrtz F, Koedel U, Pfister HW, Fontana A. Identification of a T cell chemotactic factor in the cerebrospinal fluid of HIV-1-infected individuals as interferon-gamma inducible protein 10. J Neuroimmunol 1999; 93: 172-181. (Pubitemid 29051563)
160. Rosas LE, Barbi J, Lu B, Fujiwara Y, Gerard C, Sanders VM et al. CXCR3-/- mice mount an efficient Th1 response but fail to control Leishmania major infection. Eur J Immunol 2005; 35: 515-523. (Pubitemid 40340109)
161. Hailu A, van der Poll T, Berhe N, Kager PA. Elevated plasma levels of interferon (IFN)-gamma IFN-gamma inducing cytokines, and IFN-gamma inducible CXC chemokines in visceral leishmaniasis. Am J Trop Med Hyg 2004; 71: 561-567. (Pubitemid 39601152)
162. Gupta G, Bhattacharjee S, Bhattacharyya S, Bhattacharya P, Adhikari A, Mukherjee A et al. CXC chemokine-mediated protection against visceral leishmaniasis: involvement of the proinflammatory response. J Infect Dis 2009; 200: 1300-1310.
163. Olive AJ, Gondek DC, Starnbach MN. CXCR3 and CCR5 are both required for T cell-mediated protection against C. trachomatis infection in the murine genital mucosa. Mucosal Immunol 2010 (e-pub ahead of print).
164. Belay T, Eko FO, Ananaba GA, Bowers S, Moore T, Lyn D et al. Chemokine and chemokine receptor dynamics during genital chlamydial infection. Infect Immun 2002; 70: 844-850. (Pubitemid 34083848)
165. Lee WY, Moriarty TJ, Wong CH, Zhou H, Strieter RM, van Rooijen N et al. An intravascular immune response to Borrelia burgdorferi involves Kupffer cells and iNKT cells. Nat Immunol 2010; 11: 295-302.
166. Mullegger RR, Means TK, Shin JJ, Lee M, Jones KL, Glickstein LJ et al. Chemokine signatures in the skin disorders of Lyme borreliosis in Europe: predominance of CXCL9 and CXCL10 in erythema migrans and acrodermatitis and CXCL13 in lymphocytoma. Infect Immun 2007; 75: 4621-4628. (Pubitemid 47378123)
167. Shin JJ, Glickstein LJ, Steere AC. High levels of inflammatory chemokines and cytokines in joint fluid and synovial tissue throughout the course of antibiotic-refractory lyme arthritis. Arthritis Rheum 2007; 56: 1325-1335. (Pubitemid 46608658)
168. Kondo T, Nakazawa H, Ito F, Hashimoto Y, Osaka Y, Futatsuyama K et al. Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1-type immune response. Cancer Sci 2006; 97: 780-786. (Pubitemid 43983791)
169. Zipin-Roitman A, Meshel T, Sagi-Assif O, Shalmon B, Avivi C, Pfeffer RM et al. CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res 2007; 67: 3396-3405. (Pubitemid 46724880)
170. Narvaiza I, Mazzolini G, Barajas M, Duarte M, Zaratiegui M, Qian C et al. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J Immunol 2000; 164: 3112-3122. (Pubitemid 30148972)
171. Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009; 69: 3077-3085.
172. Jones D, Benjamin RJ, Shahsafaei A, Dorfman DM. The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood 2000; 95: 627-632. (Pubitemid 30041679)
173. Jones D, O'Hara C, Kraus MD, Perez-Atayde AR, Shahsafaei A, Wu L et al. Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. Blood 2000; 96: 685-690. (Pubitemid 30463392)
174. Trentin L, Agostini C, Facco M, Piazza F, Perin A, Siviero M et al. The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. J Clin Invest 1999; 104: 115-121. (Pubitemid 29534351)
175. Sgadari C, Angiolillo AL, Cherney BW, Pike SE, Farber JM, Koniaris LG et al. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci USA 1996; 93: 13791-13796. (Pubitemid 26424199)
176. Ma X, Norsworthy K, Kundu N, Rodgers WH, Gimotty PA, Goloubeva O et al. CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Mol Cancer Ther 2009; 8: 490-498. (Pubitemid 46988082)